157 related articles for article (PubMed ID: 32519958)
1. The impact of direct-acting antiviral treatment on lipid metabolism and insulin resistance in chronic hepatitis C patients: temporary? permanent?
Özdoğan O; Yaraş S; Ateş F; Üçbilek E; Sezgin O; Altıntaş E
Turk J Gastroenterol; 2020 May; 31(5):384-392. PubMed ID: 32519958
[TBL] [Abstract][Full Text] [Related]
2. Real-world efficacy and safety of Ledipasvir + Sofosbuvir and Ombitasvir/Paritaprevir/Ritonavir ± Dasabuvir combination therapies for chronic hepatitis C: A Turkish experience.
Değertekin B; Demir M; Akarca US; Kani HT; Üçbilek E; Yıldırım E; Güzelbulut F; Balkan A; Vatansever S; Danış N; Demircan M; Soylu A; Yaras S; Kartal A; Kefeli A; Gündüz F; Yalçın K; Erarslan E; Aladağ M; Harputluoğlu M; Özakyol A; Temel T; Akarsu M; Sümer H; Akın M; Albayrak B; Sen İ; Alkım H; Uyanıkoğlu A; Irak K; Öztaşkın S; Uğurlu ÇB; Güneş Ş; Gürel S; Nuriyev K; İnci İ; Kaçar S; Dinçer D; Doğanay L; Göktürk HS; Mert A; Coşar AM; Dursun H; Atalay R; Akbulut S; Balkan Y; Koklu H; Şimşek H; Özdoğan O; Çoban M
Turk J Gastroenterol; 2020 Dec; 31(12):883-893. PubMed ID: 33626001
[TBL] [Abstract][Full Text] [Related]
3. A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: The PRIORITIZE Study.
Sulkowski MS; Moon JS; Sherman KE; Morelli G; Darling JM; Muir AJ; Khalili M; Fishbein DA; Hinestrosa F; Shiffman ML; Di Bisceglie A; Rajender Reddy K; Pearlman B; Lok AS; Fried MW; Stewart PW; Peter J; Wadsworth S; Kixmiller S; Sloan A; Vainorius M; Horne PM; Michael L; Dong M; Evon DM; Segal JB; Nelson DR;
Hepatology; 2021 Dec; 74(6):2952-2964. PubMed ID: 34255381
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort.
Calleja JL; Crespo J; Rincón D; Ruiz-Antorán B; Fernandez I; Perelló C; Gea F; Lens S; García-Samaniego J; Sacristán B; García-Eliz M; Llerena S; Pascasio JM; Turnes J; Torras X; Morillas RM; Llaneras J; Serra MA; Diago M; Rodriguez CF; Ampuero J; Jorquera F; Simon MA; Arenas J; Navascues CA; Bañares R; Muñoz R; Albillos A; Mariño Z;
J Hepatol; 2017 Jun; 66(6):1138-1148. PubMed ID: 28189751
[TBL] [Abstract][Full Text] [Related]
5. Real-world efficacy, safety, and clinical outcomes of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin combination therapy in patients with hepatitis C virus genotype 1 or 4 infection: The Turkey experience experience.
Aygen B; Demirtürk N; Yıldız O; Çelen MK; Çelik İ; Barut Ş; Ural O; Batırel A; Mıstık R; Şimşek F; Asan A; Ersöz G; Türker N; Bilgin H; Kınıklı S; Karakeçili F; Zararsız G; Turkish Society Of Clinical Microbiology And Infectious Diseases TSGFVHOT
Turk J Gastroenterol; 2020 Apr; 31(4):305-317. PubMed ID: 32412901
[TBL] [Abstract][Full Text] [Related]
6. Sustained Virological Response in Special Populations with Chronic Hepatitis C Using Interferon-Free Treatments: A Systematic Review and Meta-analysis of Observational Cohort Studies.
Ferreira VL; Leonart LP; Tonin FS; Borba HHL; Pontarolo R
Clin Drug Investig; 2018 May; 38(5):389-400. PubMed ID: 29435907
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and Safety of Interferon-Free Direct-Acting Antiviral Hepatitis C Virus Therapy in HIV/Hepatitis C Virus Coinfected Individuals: Results From a Pan-European Study.
Amele S; Peters L; Rodger A; Lundgren J; Rockstroh J; Matulionyte R; Leen C; Jabłonowska E; Østergaard L; Bhagani S; Sarcletti M; Clarke A; Falconer K; Wandeler G; Domingo P; Maltez F; Zaccarelli M; Chkhartisvili N; Szlavik J; Stephan C; Fonquernie L; Aho I; Mocroft A;
J Acquir Immune Defic Syndr; 2021 Feb; 86(2):248-257. PubMed ID: 33079903
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Ombitasvir plus Paritaprevir, Ritonavir and Ribavirin in Non-cirrhotic Treatment-naïve and Treatment-experienced Egyptians with Chronic HCV Genotype-4 Infection.
Ahmed M; Mansey AE; Wahsh EA; Gomaa AA; Rabea HM
Curr Med Sci; 2021 Jun; 41(3):581-586. PubMed ID: 34047942
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of Sofosbuvir, Ledipasvir/Sofosbuvir, or Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir Regimens for Treatment of Patients With Hepatitis C in the Veterans Affairs National Health Care System.
Ioannou GN; Beste LA; Chang MF; Green PK; Lowy E; Tsui JI; Su F; Berry K
Gastroenterology; 2016 Sep; 151(3):457-471.e5. PubMed ID: 27267053
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir ± Ribavirin for HCV in Brazilian Adults with Advanced Fibrosis.
Pessoa MG; Ramalho-Madruga JV; Alves K; Nunes EP; Cheinquer H; Brandão-Mello CE; Mendes-Correa MC; Ferraz ML; Ferreira PRA; Álvares-da-Silva MR; Coelho HS; Affonso-de-Araújo ES; Furtado J; Parana R; Silva G; Lari SA; Liu L; Tripathi R; Pilot-Matias T; Cohen DE; Shulman NS; Martinelli A
Ann Hepatol; 2018 Oct; 17(6):959-968. PubMed ID: 30600291
[TBL] [Abstract][Full Text] [Related]
11. Real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan.
Liu CH; Liu CJ; Su TH; Yang HC; Hong CM; Tseng TC; Chen PJ; Chen DS; Kao JH
J Gastroenterol Hepatol; 2018 Mar; 33(3):710-717. PubMed ID: 28762541
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness, treatment completion and safety of sofosbuvir/ledipasvir and paritaprevir/ritonavir/ombitasvir + dasabuvir in patients with chronic kidney disease: an ERCHIVES study.
Butt AA; Ren Y; Puenpatom A; Arduino JM; Kumar R; Abou-Samra AB
Aliment Pharmacol Ther; 2018 Jul; 48(1):35-43. PubMed ID: 29797514
[TBL] [Abstract][Full Text] [Related]
13. Sofosbuvir, Glecaprevir, Pibrentasvir, and Ribavirin as a Rescue Therapy in Difficult-to-Treat HCV Patients.
Meszaros M; Truchi R; Ouzan D; Tran A; Bourlière M; Pageaux GP
Hepatology; 2021 Oct; 74(4):2304-2306. PubMed ID: 34008214
[No Abstract] [Full Text] [Related]
14. Effectiveness of 8- and 12-Week Treatment with Ombitasvir/ Paritaprevir/Ritonavir and Dasabuvir in Treatment-Naïve HCV Patients in a Real-Life Setting in Romania: the AMETHYST Study.
Trifan A; Stanciu C; Iliescu L; Sporea I; Baroiu L; Diculescu M; Luca MC; Miftode E; Cijevschi C; Mihai C; Sparchez ZA; Pojoga C; Streinu-Cercel A; Gheorghe L
J Gastrointestin Liver Dis; 2021 Mar; 30(1):88-93. PubMed ID: 33723561
[TBL] [Abstract][Full Text] [Related]
15. Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic hepatitis C virus, genotype 1-infected patients.
Meissner EG; Lee YJ; Osinusi A; Sims Z; Qin J; Sturdevant D; McHutchison J; Subramanian M; Sampson M; Naggie S; Patel K; Remaley AT; Masur H; Kottilil S
Hepatology; 2015 Mar; 61(3):790-801. PubMed ID: 25203718
[TBL] [Abstract][Full Text] [Related]
16. High success rates for the use of sofosbuvir/ombitasvir/paritaprevir/ritonavir + ribavirin and sofosbuvir/simeprevir/daclatasvir + ribavirin in retreatment of chronic hepatitis C infection after unsuccessful sofosbuvir/daclatasvir therapy: a real-life experience.
Said EM; Abdulaziz BA; El Kassas M; El Attar IH; Emadeldeen M; Abd-Elsalam SM
Arch Virol; 2020 Jul; 165(7):1633-1639. PubMed ID: 32356185
[TBL] [Abstract][Full Text] [Related]
17. Efficacy, Safety, and Predictors of Direct-acting antivirals in Hepatitis C Virus Patients with Heterogeneous Liver Diseases.
De Pace V; Morelli MC; Ravaioli M; Maggi F; Galli S; Vero V; Re MC; Cescon M; Pistello M
New Microbiol; 2019 Oct; 42(4):189-196. PubMed ID: 31609453
[TBL] [Abstract][Full Text] [Related]
18. Emergence of drug resistance-associated variants and changes in serum lipid profiles in sofosbuvir plus ledipasvir-treated chronic hepatitis C patients.
Kan H; Imamura M; Kawakami Y; Daijo K; Teraoka Y; Honda F; Nakamura Y; Morio K; Kobayashi T; Nakahara T; Nagaoki Y; Kawaoka T; Tsuge M; Aikata H; Hayes CN; Miki D; Ochi H; Honda Y; Mori N; Takaki S; Tsuji K; Chayama K
J Med Virol; 2017 Nov; 89(11):1963-1972. PubMed ID: 28657143
[TBL] [Abstract][Full Text] [Related]
19. Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12weeks.
Feld JJ; Moreno C; Trinh R; Tam E; Bourgeois S; Horsmans Y; Elkhashab M; Bernstein DE; Younes Z; Reindollar RW; Larsen L; Fu B; Howieson K; Polepally AR; Pangerl A; Shulman NS; Poordad F
J Hepatol; 2016 Feb; 64(2):301-307. PubMed ID: 26476290
[TBL] [Abstract][Full Text] [Related]
20. Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis.
Lim JK; Liapakis AM; Shiffman ML; Lok AS; Zeuzem S; Terrault NA; Park JS; Landis CS; Hassan M; Gallant J; Kuo A; Pockros PJ; Vainorius M; Akushevich L; Michael L; Fried MW; Nelson DR; Ben-Ari Z;
Clin Gastroenterol Hepatol; 2018 Nov; 16(11):1811-1819.e4. PubMed ID: 29306043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
